Enantia

Enantia is a well-established, private Spanish CRO founded in 2003, specializing in small molecule and drug delivery chemistry services. The company leverages a highly qualified team, with over 60% holding PhDs, to deliver route scouting, optimization, solid-form screening, and analytical services for global biotech and pharma clients. Its recent acquisition by INVACO provides a foundation for expansion, while its ISO certification and strong patent contribution record underscore its commitment to quality and innovation. Enantia's business model is purely service-based, generating revenue through contracted R&D work.

Integrated suite of chemistry services including synthetic route design, process R&D, continuous flow chemistry, solid-state form (polymorph/salt/cocrystal) screening, and analytical development, with specialized capabilities for Highly Potent APIs (HPAPIs).

Operates in the highly competitive global CRO market, competing against large full-service CROs (e.g., LabCorp, IQVIA) and numerous niche chemistry specialists. Differentiates through deep, PhD-heavy expertise in complex synthetic and solid-state chemistry, and specialized HPAPI handling.